Metformin is widely used as oral anti-hyperglycaemic agent to treat Type 2 diabetes, with increasing reports of an additional, potential bone protective role. On a cellular level, mesenchymal stem cells (MSCs) have
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Confluent murine MSCs (C3H10T1/2) were treated with metformin (500μM), a known AMPK activator (A769662;100μM) or the p70S6K inhibitor (rapamycin;10μM), in both control and adipogenic-inducing environments (using pioglitazone;10μM) for 5 days. Nuclear extracts were separated by SDS-PAGE and immunoblotted with primary antibodies to peroxisome proliferator-activated receptor gamma (PPARγ;marker for adipogenesis), Runt-related transcription factor 2 (Runx2;marker for osteogenesis), phosphorylated-ACC (P-ACC(Ser79);marker for AMPK activity) and phosphorylated-p70s6k (P-p70s6k(Thr389); upstream regulator of mTOR signalling). Immunoblots were scanned using a Licor fluorescent reader. PPARγ and Runx2 activities were determined using Luciferase reporter assays and adipogenesis was quantified histochemically by staining neutral lipids with Oil Red O. • Metformin inhibits adipogenesis and promotes osteogenesis
• Acting through AMPK-independent pathway, involving the suppression of p70s6k in the mTOR signalling (novel mechanism of action)
• Rationale for the reported bone protective role of metformin been reported to have reciprocal differentiation into bone at the expense of fat, and vice versa. We set out to investigate the effects of metformin on the multipotent mesenchymal stem cell differentiation and the underlying molecular mechanism(s) involved. ** ** ns ns ns
